Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696779 | 1.00 | USP30 (0.56) | USP30STSGPR119JAK2JAK1 | |
| SCHEMBL29043109 | 1.00 | USP30 (0.56) | USP30STSGPR119JAK2JAK1 | |
| SCHEMBL22222650 | 0.93 | USP30 (0.62) | USP30STSGPR119JAK2JAK1 | |
| SCHEMBL28779687 | 0.93 | USP30 (0.62) | USP30STSGPR119JAK2JAK1 | |
| SCHEMBL616004 | 0.93 | STS (0.60) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL28779718 | 0.92 | USP30 (0.58) | USP30STSGPR119JAK2JAK1 | |
| SCHEMBL28779720 | 0.92 | USP30 (0.58) | USP30STSGPR119JAK2JAK1 | |
| SCHEMBL9937172 | 0.90 | STS (0.50) | USP30STSGPR119JAK2JAK1 | |
| SCHEMBL20794854 | 0.89 | GPR119 (0.52) | USP30GPR119ACHEBCHEBACE1 | |
| SCHEMBL651891 | 0.88 | HTT (0.53) | USP30STSGPR119ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116103257-B | Reductive amination enzyme mutant and application thereof in synthesis of alkylated pyrrolidine chiral amine | 中国科学院天津工业生物技术研究所 | 2024-10-29 | — | — | CN | disclosed |
| CN-114717211-B | Imine reductase mutant M5 and application thereof in synthesis of nitrogen heterocycle chiral amine | 江苏集萃分子工程研究院有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116103257-A | Reductive amination enzyme mutant and application thereof in synthesis of alkylated pyrrolidine chiral amine | 中国科学院天津工业生物技术研究所 | 2023-05-12 | — | — | CN | disclosed |
| CN-114717211-A | Imine reductase mutant M5 and application thereof in synthesis of azacyclo chiral amine | 江苏集萃分子工程研究院有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8124773-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | USP30 2665/4885STS 4701/4885GPR119 639/4885 |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | USP30 3728/4885STS 972/4885GPR119 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.